Updates
** Shares of Neumora Therapeutics NMRA.O fall 11.2% to $1.35 premarket, set to break three-day winning streak
** Johnson & Johnson JNJ.N late on Thursday scrapped trials of a depression drug similar to NMRA's navacaprant, citing lack of sufficient efficacy
** Brokerage Stifel, which was one among six joint bookrunners of NMRA's IPO in 2023, cuts rating to "hold" from "buy"
** "We had always seen the success of aticaprant... as an important source of validation for the KORA mechanism," says Stifel, referring to class of drugs known as KOR antagonists
** NMRA stock plunged about 80% in early January after experimental drug navacaprant flunked late-stage trial in depression patients
** Shares down about 90% since IPO in September 2023
(Reporting by Manas Mishra)
((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。